Toe the line or face the fine (5% of EU turnover)
This article was originally published in Scrip
Legal experts are advising pharmaceutical companies to carefully review the recently amended EU Penalties Regulation, under which certain infringements of paediatric and pharmacovigilance laws for centrally authorised drugs can now lead to financial penalties of up to 5% of the marketing authorisation holder's annual EU turnover. The amended regulation came into force on 2 July.
You may also be interested in...
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.